Sandu Pharma: Audited Financials for FY26, ₹1 Dividend

Sandu Pharmaceuticals Ltd announced audited financial results for the quarter and year ended March 31, 2026, following a Board Meeting on May 5, 2026. The board approved the standalone audited financial results and recommended a final dividend of ₹1 per equity share (10% on paid-up share capital), subject to shareholder approval. They also appointed M/s Shekhar Joshi & Co as Cost Auditor for FY 2026-27 and M/S Akhil Pai & Co and M/S Uday & Uday Associates as Internal Auditors for Goa and Mumbai plants respectively. The board also took note of the Statement of Utilizations and Deviations as per Regulation 32 of SEBI (LODR) Regulation 2015.